Depression Therapeutics Market Size, Share, Trends, and Forecast 2018 - 2026

1. DEPRESSION THERAPEUTICS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Depression Therapeutics - Overview The global depression therapeutics market, by drug type (Antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Serotonin Modulators, Tricyclic & Tetracyclic Antidepressants and Atypical Antidepressants), Antipsychotics and Others), by indication (Major Depressive Disorder (MDD), Bipolar Disorder, Dysthymic Disorder, Postpartum Depression, Seasonal Affective Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), and Others), by distribution channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa), was pegged at US$ 11,130.7 million in 2017 and is forecast to exhibit a CAGR of 3.7% over the forecast period (2018-2026). Generic drug manufacturers have witnessed a major upsurge in demand for antidepressant medications over the recent past, owing to the growing prevalence of mental disorders, such as depression, anxiety, and bipolar disorders, across the globe. However, branded drug manufacturers are focused on gaining profits on patented products, such as Viibryd, manufactured by Forest Laboratories. The global healthcare space has witnessed the advent of innovative generic counterparts of branded products in past few years. Browse Research Reports: https://www.coherentmarketinsights.com/market- © Coherent market Insights. All Rights Reserved insight/depression-therapeutics-market-1307

3. REPORT DESCRIPTION Allergan Plc’s Fetzima is protected by three patents that are expected to expire in 2031, 2032, and 2023, each. Multiple major drug manufacturers have received the U.S. Food & Drug Administration (FDA) approval for the commercialization of several antidepressant drugs. For instance, Levomilnacipran received the U.S. FDA approval in 2013, under brand name Fetzima by Forest Laboratories, Inc. Allergan Plc. and its partner Gedeon Richter Plc. receive FDA approval for Vraylar (cariprazine) for the treatment of manic or mixed episodes of bipolar I disorder and Intellipharmaceutics International Inc. received approval from the U.S. Food and Drug Administration for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300, and 400 mg strengths. schizophrenia among adults. In 2017, The leading market contenders are majorly involved in various R&D activities, which is a developmental aspect for the growth of the global depression therapeutics market. For instance, GlaxoSmithKline Plc, together with University of Cambridge and Janssen Pharmaceuticals formed an MRC Immunopsychiatry Consortium in 2017, in order to investigate the links between depression and inflammation. Allergan Plc's Vraylar (cariprazine) cleared the phase III trial, while Rapastine is still undergoing the phase II trial and is likely to receive approval by 2022. In 2017, Allergan Plc., along with its partner Gedeon Richter Plc, succeeded in the phase 3 study of cariprazine for the treatment of major depressive episodes among adults. Request a Sample copy of this reports :https://www.coherentmarketinsights.com/insight/request-sample/1307 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Key Takeaways of the Global Depression Therapeutics Market: • Holdings and Takeda Pharmaceutical Company Limited, which are known to capitalize on generic products sale in this region and focus on collaborations for higher profits. This is a pivotal factor fostering the Asia Pacific depression therapeutics market expansion. There is a high presence of major manufacturers, such as Otsuka • period, owing to multiple patent losses of potential blockbuster drugs and introduction of new drugs that are currently in later stages of clinical trials. The market is expected to witness positive changes over the forecast • market include Pfizer, Inc., Eli, Lilly and Company, AstraZeneca, Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co., Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceuticals Co., Ltd., and Chengdu Kanghong Pharmaceutical Group Co., Ltd. The renowned players operating in the global depression therapeutics Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1307 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved